1910 Genetics Appoints Bridget Cole To Chief Scientific Officer
11/18/23, 4:58 AM
Location
bostonIndustry
machine learning
artificial intelligence
biotechnology
Position
chief scientific officer
1910 Genetics, the only biotech advancing small and large molecule drug discovery with an automated, multimodal AI platform, today announced the appointment of Bridget Cole to Chief Scientific Officer. Cole, who previously served as SVP and Head of Chemistry, will lead the biotech’s scientific research operations, set and advance research priorities, and work closely with 1910’s AI leadership to guide model and platform development with her drug development expertise.
Company Info
Location
labcentral
boston, massachusetts, united states
Additional Info
1910 Genetics is the only biotech company advancing small and large molecule drug discovery with an automated, multimodal AI platform. We integrate AI with three proprietary data streams – computational data, wet lab gold standard biological data and wet lab proxy biological data – to deliver novel drug candidates to leading pharma and tech partners, and advance our own pipeline for neurological, autoimmune diseases, and cancer. 1910 was launched in 2021 with a combined seed and Series A funding of $26.1M backed by M12-Microsoft’s Venture Fund, Playground Global, OpenAI’s Sam Altman, and other leading investors. We have since established our HQ and lab facilities in Boston’s Seaport District and continue to hire a world-class team. To learn more visit 1910genetics.com.